Atezolizumab and sacituzumab to prevent breast cancer return
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer was triple-negative (ER <10% and PR <10%), and HER2 is negative
- After pre-surgery (neoadjuvant) chemotherapy, you had residual invasive cancer in the breast and/or lymph nodes (or in lymph nodes at least 2 mm)
- You finished all local treatment (surgery and required radiation) within the last 4 months, with clear margins
- A blood test after therapy (ctDNA) must find tumor DNA mutations on a central lab test
- You can safely take study medicines: good blood counts and organ function, and ECOG performance status 0–1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.